<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2813">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351243</url>
  </required_header>
  <id_info>
    <org_study_id>KIN-1901-2001</org_study_id>
    <nct_id>NCT04351243</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)</brief_title>
  <official_title>A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinevant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roivant Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kinevant Sciences GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled&#xD;
      study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute&#xD;
      respiratory distress syndrome (ARDS) secondary to COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gimsilumab is a monoclonal antibody against granulocyte macrophage-colony stimulating factor&#xD;
      (GM-CSF), which is a myeloid cell growth factor and pro- inflammatory cytokine. Late stages&#xD;
      of COVID-19 can be marked by a &quot;cytokine storm&quot; and the overactivation of inflammatory&#xD;
      myeloid cells that infiltrate and damage tissue, such as the lungs. Inhibition of GM-CSF may&#xD;
      be able to reverse this pathology. The anti-GM-CSF mechanism is distinct from antiviral&#xD;
      therapeutic mechanisms and may provide synergistic effects when used in combination.&#xD;
&#xD;
      Study KIN-1901-2001 will consist of a 2-week treatment period (last dose Day 8, if&#xD;
      administered) and a 22-week follow-up period, for a total study duration of 24 weeks for each&#xD;
      subject. A total of 270 subjects (135 subjects per arm) who have a confirmed diagnosis of&#xD;
      COVID-19 with clinical evidence of acute lung injury or ARDS will be entered into the trial.&#xD;
&#xD;
      Subjects will receive a high dose of gimsilumab on Day 1 and a low dose of gimsilumab on Day&#xD;
      8, or matching placebo (saline solution) on Day 1 and on Day 8. The Day 8 dose will be&#xD;
      omitted if the subject is discharged from the hospital or is no longer in need of&#xD;
      supplemental oxygen or ventilatory support for &gt;48 hours.&#xD;
&#xD;
      The primary objective of Study KIN-1901-2001 is to evaluate the impact of IV treatment with&#xD;
      gimsilumab on mortality in subjects with lung injury or ARDS secondary to COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 12, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects who are alive and not on mechanical ventilation</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Subjects who die will be assigned &quot;0&quot; ventilator-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>Baseline to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Gimsilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gimsilumab high dose on Day 1 Gimsilumab low dose on Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline on Day 1 Normal saline on Day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimsilumab</intervention_name>
    <description>Gimsilumab is a fully human monoclonal antibody (mAb).</description>
    <arm_group_label>Gimsilumab</arm_group_label>
    <other_name>KIN-1901</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female age â‰¥18 years, inclusive&#xD;
&#xD;
          2. Subject (or legally authorized representative) is able and willing to provide written&#xD;
             informed consent, which includes compliance with study requirements and restrictions&#xD;
             listed in the consent form&#xD;
&#xD;
          3. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other approved&#xD;
             clinical testing prior to randomization&#xD;
&#xD;
          4. Radiographic evidence of bilateral infiltrates&#xD;
&#xD;
          5. Subject requires high-flow oxygen or meets clinical classification for ARDS&#xD;
&#xD;
          6. Elevated serum CRP or ferritin&#xD;
&#xD;
          7. Subjects who have been treated with convalescent plasma prior to enrollment are&#xD;
             eligible if the subject continues to meet all entry criteria at screening&#xD;
&#xD;
          8. The use of investigational antiviral treatments (e.g., remdesivir, hydroxychloroquine)&#xD;
             is allowed during the study&#xD;
&#xD;
        Additional inclusion criteria are detailed in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of life-threatening dysrhythmia or cardiac arrest on presentation&#xD;
&#xD;
          2. Intubated &gt;72 hours&#xD;
&#xD;
          3. Absolute neutrophil count &lt; 1,000 per mm3&#xD;
&#xD;
          4. Platelet count &lt; 50,000 per mm3&#xD;
&#xD;
          5. AST or ALT &gt; 5X upper limit of normal&#xD;
&#xD;
          6. eGFR &lt;30 mL/min/1.73m2 or requiring hemofiltration or dialysis&#xD;
&#xD;
          7. History of known anti-GM-CSF autoantibodies or pulmonary alveolar proteinosis&#xD;
&#xD;
          8. Severe chronic respiratory disease (e.g., COPD, PAH, IPF, ILD) requiring supplemental&#xD;
             oxygen therapy or mechanical ventilation pre-hospitalization (e.g., prior to COVID-19&#xD;
             diagnosis)&#xD;
&#xD;
          9. Known or suspected active and untreated TB, HIV, hepatitis B or C infection&#xD;
&#xD;
        Additional exclusion criteria are detailed in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth John C. Lincoln Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Osborn Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Ronald Reagan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Jefferson General Hospital</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Jack &amp; Jane Hamilton Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulocyte macrophage-colony stimulating factor (GM-CSF)</keyword>
  <keyword>Immunomodulator</keyword>
  <keyword>Cytokine storm</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Severe Acute Respiratory Syndrome (SARS)</keyword>
  <keyword>Lung Injury</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

